Concordia International Corp’s Trend Up, Especially After Today’s Strong Session


 Concordia International Corp's Trend Up, Especially After Today's Strong Session

The stock of Concordia International Corp (TSE:CXR) is a huge mover today! About 87,948 shares traded hands. Concordia International Corp (TSE:CXR) has declined 89.90% since March 11, 2016 and is downtrending. It has underperformed by 95.38% the S&P500.
The move comes after 9 months positive chart setup for the $238.41M company. It was reported on Oct, 18 by We have $7.34 PT which if reached, will make TSE:CXR worth $121.59M more.

Concordia International Corp (TSE:CXR) Ratings Coverage

Out of 4 analysts covering Concordia Healthcare Corp (TSE:CXR), 1 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 25% are positive. $135 is the highest target while $4.50 is the lowest. The $32.70 average target is 572.84% above today’s ($4.86) stock price. Concordia Healthcare Corp has been the topic of 21 analyst reports since August 11, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the shares of CXR in a report on Tuesday, June 7 with “Outperform” rating. Scotia Capital maintained Concordia International Corp (TSE:CXR) rating on Wednesday, September 9. Scotia Capital has “Sector Outperform” rating and $100 price target. Goldman Sachs maintained it with “” rating and $34 target price in Friday, July 22 report. The rating was downgraded by Mackie on Thursday, December 3 to “Hold”. The rating was maintained by RBC Capital Markets on Monday, June 20 with “Outperform”. The stock has “Outperform” rating given by RBC Capital Markets on Monday, May 16. The stock has “Outperform” rating given by RBC Capital Markets on Monday, October 17. RBC Capital Markets maintained Concordia International Corp (TSE:CXR) on Friday, January 8 with “Outperform” rating. The stock has “Outperform” rating given by RBC Capital Markets on Tuesday, August 11. The company was maintained on Tuesday, October 11 by RBC Capital Markets.

More important recent Concordia International Corp (TSE:CXR) news were published by: which released: “Concordia International Corp. faces much more downside – CIBC” on October 14, 2016, also published article titled: “Concordia International Corp takeover unlikely – Goldman”, published: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” on September 29, 2016. More interesting news about Concordia International Corp (TSE:CXR) was released by: and their article: “Moody’s assigns B1 to Concordia’s new secured notes; outlook to negative” with publication date: October 06, 2016.

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada pharmaceutical company. The company has a market cap of $238.41 million. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. It currently has negative earnings.

CXR Company Profile

CSX Corporation, together with its subsidiaries, incorporated on November 15, 1978, is a transportation company. The Firm provides rail transportation services, including rail service and the transport of intermodal containers and trailers. The Firm serves approximately three lines of business, such as merchandise business, coal business and intermodal business. The Company’s operating subsidiary, CSX Transportation, Inc. (CSXT), provides a link to the transportation supply chain through its approximately 21,000-route mile rail network, which serves population centers in approximately 20 states east of the Mississippi River, the District of Columbia and the Canadian provinces of Ontario and Quebec. It has access to over 70 ocean, river and lake port terminals along the Atlantic and Gulf Coasts, the Mississippi River, the Great Lakes and the St. Lawrence Seaway. The Company’s intermodal business links clients to railroads through trucks and terminals. CSXT also serves production and distribution facilities through track connections to approximately 240 short-line and regional railroads.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply